Now showing items 58-77 of 84

      Pandemrix vaccine: why was the public not told of early warning signs? [1]
      Patient consent to publication and data sharing in industry and NIH-funded clinical trials [2]
      Popular and scientific attitudes regarding pandemic influenza [1]
      The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? [1]
      Preventing flu-like illness: Reason for optimism [1]
      The problem with US website for collecting adverse events after vaccination is resolved [1]
      Putting GlaxoSmithKline to the test over paroxetine [1]
      Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling. [1]
      Restoring biomedical literature with RIAT [1]
      Restoring invisible and abandoned trials: a call for people to publish the findings [1]
      Rethinking credible evidence synthesis [1]
      Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports [1]
      Speeding new antibiotics to market: a fake fix? [1]
      Statins for primary prevention: what is the regulator’s role? [1]
      Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19 [1]
      Trends in recorded influenza mortality: United States, 1900-2004 [1]
      The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? [1]
      Update: New England Journal of Medicine publishes correction to 2012 CHEST trial of hydroxyethyl starch versus colloids [1]
      US government website for collecting adverse events after vaccination is inaccessible to most users [1]
      US incentive scheme for neglected diseases: a good idea gone wrong? [1]